Can montelukast correct immune dysregulation in preschool children with mild persistent asthma?
El-Kelany, A., Anani, M., Omar, H., Hashem, A., Fathy, E. (2019). Can montelukast correct immune dysregulation in preschool children with mild persistent asthma?. EKB Journal Management System, 17(2), 87-95. doi: 10.21608/ejpa.2019.53993
Amany El-Kelany; Maha Anani; Hanan Omar; Asmaa Hashem; Enas Fathy. "Can montelukast correct immune dysregulation in preschool children with mild persistent asthma?". EKB Journal Management System, 17, 2, 2019, 87-95. doi: 10.21608/ejpa.2019.53993
El-Kelany, A., Anani, M., Omar, H., Hashem, A., Fathy, E. (2019). 'Can montelukast correct immune dysregulation in preschool children with mild persistent asthma?', EKB Journal Management System, 17(2), pp. 87-95. doi: 10.21608/ejpa.2019.53993
El-Kelany, A., Anani, M., Omar, H., Hashem, A., Fathy, E. Can montelukast correct immune dysregulation in preschool children with mild persistent asthma?. EKB Journal Management System, 2019; 17(2): 87-95. doi: 10.21608/ejpa.2019.53993

Can montelukast correct immune dysregulation in preschool children with mild persistent asthma?

The Egyptian Journal of Pediatric Allergy and Immunology
Article 6, Volume 17, Issue 2, October 2019, Page 87-95  XML PDF (312.7 K)
Document Type: Original Article
DOI: 10.21608/ejpa.2019.53993
View on SCiNiTO View on SCiNiTO
Authors
Amany El-Kelany1; Maha Anani2; Hanan Omar3; Asmaa Hashemorcid 4; Enas Fathy1
1Department of Pediatrics, faculty of medicine, Suez Canal University, Ismailia, Egypt.
2Clinical pathology department, faculty of medicine, Suez Canal University, Ismailia, Egypt.
3Clinical pathology, faculty of medicine, Suez Canal University, Ismailia,Egypt.
4Microbiology and Immunology department, faculty of medicine, Suez Canal University, Ismailia, Egypt.
Abstract
Background: Asthma is the most common inflammatory disorder among
preschool and school-age children. Regulation of immune cells and their
cytokines is essential to control asthma. Montelukast is a leukotriene
receptor antagonist that suppresses inflammatory cell proliferation, and
reduces cytokines and mediator secretion. Objective: The research
team's goal was to study the immunological parameters among mild
asthmatic patients before and after the treatment with Montelukast .
Methods: Forty preschool children with mild persistent asthma and
twenty healthy, non-allergic children were included in the study. Blood
eosinophil count, total IgE, serum IL-4, IL-10, and IL-13 levels were
assessed. T helper (CD3+CD4+) and T regulatory (CD4+CD25+) cell
counts were measured using flow cytometry; for mild asthmatics before
and after six weeks of treatment with Montelukast and for the control
group. Results: Asthmatic children have shown a significant elevation of
serum levels of IgE, IL4 and IL13, and also an increase of eosinophils,
total lymphocyte T cells and T helper cell count. However; serum levels
of IL10 and Treg cell count was lower in asthmatics compared to control.
Following six weeks of Montelukast treatment, all immunological
parameters improved. There was a significant elevation of serum levels
of IL10 and Treg cell count, with a decrease in serum levels of IgE, IL4
and IL13; eosinophil counts, and helper T cells. Conclusion:
Montelukast treatment improves the impaired immunological balance of
mild asthmatic children through the increase of serum IL-10, T
regulatory cell counts that have anti-inflammatory and
immunoregulatory effects. It also decreases T helper cells and their
proinflammatory cytokines.
Keywords
Montelukast; Asthma; children; Egypt
Statistics
Article View: 334
PDF Download: 283